Form 4: Turnstone Biologics Director Acquires Stock Options
SEC Filing Form 4
William D. Waddill, a director of Turnstone Biologics Corp., acquired stock options exercisable for 12,770 shares of common stock on June 3, 2024.
Summary
- On July 2, 2024, a Form 4 filing was submitted to the SEC, reporting a change in beneficial ownership for William D. Waddill, a director of Turnstone Biologics Corp.
- The transaction involved the acquisition of stock options, granting the right to buy 12,770 shares of Turnstone Biologics Corp.'s common stock.
- The exercise price of the stock options is $2.69 per share.
- The options were granted on June 3, 2024, and expire on June 2, 2034.
- The options will vest on the earlier of June 3, 2025, or the date of the next annual meeting of stockholders, contingent upon the director's continuous service.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It reflects a standard transaction (stock option grant) for a company director. It doesn't inherently indicate positive or negative prospects for the company, but rather a routine part of executive compensation.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting of the options is tied to the director's continued service and the company's annual meeting.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment, as it could be interpreted as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/03/2024 | Date of earliest transaction: Acquisition of stock options. |
| 06/03/2025 | Vesting date of the stock options, contingent on continuous service, or earlier if the next annual meeting of stockholders occurs before this date. |
| 06/02/2034 | Expiration date of the stock options. |
| 07/02/2024 | Date of Form 4 filing. |
Keywords
Form 4, Turnstone Biologics, Stock Options, Beneficial Ownership, Director, TSBX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.